Jade Biosciences (JBIO) Times Interest Earned (2021 - 2024)
Jade Biosciences' (JBIO) quarterly Times Interest Earned came in at -$40.99 in Q1 2026, down 390.76% YoY from $14.1 in Q1 2025, and down 4283.38% on a QoQ basis from -$0.94 in Q3 2025.
Analysis
Jade Biosciences (JBIO) Times Interest Earned (2021 - 2024) Analysis & Trends
Jade Biosciences (JBIO) has 7 years of Times Interest Earned data on file, last reported at -$40.99 in Q1 2026.
- Quarterly Times Interest Earned fell 390.76% year-over-year to -$40.99 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$126.04 (down 256.8% YoY) and the FY2025 annual result came in at -$31.54, down 219.47% from the prior year.
- Times Interest Earned eased to -$40.99 in Q1 2026, from -$0.94 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $226.46 in Q4 2022 to a low of -$1296.2 in Q3 2024.
- A 5-year average of -$89.78 and a median of -$0.68 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned soared 99.99% — and 2024, when it plunged 107571.01%.
- Tracing JBIO's Times Interest Earned over 5 years: stood at $226.46 in 2022, then tumbled by 181.88% to -$185.43 in 2023, then sank by 599.06% to -$1296.2 in 2024, then jumped by 99.93% to -$0.94 in 2025, then plunged by 4283.38% to -$40.99 in 2026.
- The last three Times Interest Earned figures came in at -$40.99 (Q1 2026), -$0.94 (Q3 2025), and -$0.66 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Jade Biosciences | 1.21 Bn | 1.21 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -4,360.83 |
| Mar 31, 2024 | -8,206.00 |
| Jun 30, 2023 | -20,336.00 |
| Mar 31, 2023 | -17,639.00 |
| Jun 30, 2022 | -2,035.83 |
| Dec 31, 2021 | 8,268.00 |
| Jun 30, 2021 | -1,924.67 |
| Mar 31, 2021 | -2,780.00 |